A new publication involving pasireotide was reported on September 23, 2026. The article, titled "Pasireotide-LAR and pegvisomant combination in resistant acromegaly: a case series of predominantly mammosomatotroph adenomas," appeared in the journal Pituitary.
The publication is described as a case series focused on patients with resistant acromegaly. It examines the use of pasireotide-LAR in combination with pegvisomant, with the case series noted as predominantly involving mammosomatotroph adenomas.
No additional details about findings, outcomes, or conclusions were provided in the event data. This brief reports only that the publication exists and its stated title, journal, and date, without characterizing any results.
Pasireotide is an approved compound. Readers interested in background on its approved uses and general profile can consult the compound overview for further context.